Frontotemporal Dementia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Frontotemporal Dementia Marketed and Pipeline Drugs Report Overview
Frontotemporal dementia (FTD) is one of the most common forms of early-onset dementia affecting individuals before the age of 65. It is also known as frontotemporal lobar degeneration (FTLD), referring to a group of neurodegenerative brain disorders predominantly affecting the frontal and anterior temporal lobes.
The FTD marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in major countries. Furthermore, the report analyzes late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for frontotemporal dementia.
The report also provides actionable insights into the clinical and commercial landscapes of frontotemporal dementia, M&A deals, and market catalysts. These critical data will help you develop and design your in-licensing and out-licensing strategies. Furthermore, identify companies with the most robust pipelines to create smart business goals.
| Key Mechanisms of Action (Pipeline) | · Protein and Peptide Inhibitors
· Enzyme Inhibitors · Receptor Agonists · Biological Factor Activators · Biological Factor Inhibitors |
| Key Molecule Types (Pipeline) | · Small Molecule
· Biologic · Oligonucleotide |
| Top Sponsors (Marketed and Pipeline Drugs) | · Denali Therapeutics Inc
· Alector Inc · Wave Life Sciences Ltd · Passage Bio Inc · Foundation Santa Lucia |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Frontotemporal Dementia Pipeline Drugs Market Segmentation by Mechanisms of Action
The key MoA of the drugs in the frontotemporal dementia pipeline mainly includes protein and peptide inhibitors, enzyme inhibitors, receptor agonists, biological factor activators, and biological factor inhibitors, among others. Most of the pipeline drugs for FTD follow protein and peptide inhibitors MoA in 2024.
Frontotemporal Dementia Pipeline Drugs Market Analysis by Mechanisms of Action, 2024 (%)
Buy the Full Report to Know More about the MoA of Frontotemporal Dementia Pipeline Drugs
Frontotemporal Dementia Pipeline Drugs Market Segmentation by Molecule Types
In 2024, the leading molecule type for frontotemporal dementia pipeline drugs is biologics followed by small molecules. The other drugs currently in development are oligonucleotide types.
Frontotemporal Dementia Pipeline Drugs Market Analysis by Molecule Types, 2024 (%)
Buy the Full Report to Know More about the Molecule Types of Frontotemporal Dementia Pipeline Drugs
Frontotemporal Dementia Marketed and Pipeline Drugs Market – Competitive Landscape
A few of the top sponsors in frontotemporal dementia marketed and pipeline drugs market are Denali Therapeutics Inc, Alector Inc, Wave Life Sciences Ltd, Passage Bio Inc, and Foundation Santa Lucia, among others. Denali Therapeutics Inc and Alector Inc are both sponsoring the highest number of trials in 2024.
Frontotemporal Dementia Marketed and Pipeline Drugs Market Analysis by Sponsors, 2024 (%)
Buy the Full Report for More Sponsor Insights into the Frontotemporal Dementia Marketed and Pipeline Drugs Market
Download a Free Report Sample
Segments Covered in the Report
Frontotemporal Dementia Pipeline Drugs Mechanisms of Action Outlook (2024)
- Protein and Peptide Inhibitors
- Enzyme Inhibitors
- Receptor Agonists
- Biological Factor Activators
- Biological Factor Inhibitors
- Enzyme Activators
- Ion Channel Blockers
- Ion Channel Activators
- Receptor Antagonists
- Receptor Inhibitors
- Protein and Peptide Activators
Frontotemporal Dementia Pipeline Drugs Molecule Types Outlook (2024)
- Small Molecule
- Biologic
- Oligonucleotide
Scope
The key components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Frontotemporal Dementia market.
- Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Frontotemporal Dementia market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which is the leading MoA for frontotemporal dementia pipeline drugs in 2024?
Most of the drugs follow protein and peptide inhibitor MoA in 2024 in the frontotemporal dementia pipeline drugs market.
-
Which is the leading molecule type for frontotemporal dementia pipeline drugs in 2024?
In 2024, most of the drugs in development for frontotemporal dementia are biologics.
-
Which are the top sponsors in the frontotemporal dementia marketed and pipeline drugs market?
A few of the top sponsors in the frontotemporal dementia marketed and pipeline drugs market are Denali Therapeutics Inc, Alector Inc, Wave Life Sciences Ltd, Passage Bio Inc, and Foundation Santa Lucia, among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Dementia reports


